Uliledlimab

I-Mab is prioritizing givastomig, a CLDN18.2 x 4-1BB bispecific antibody, as its lead clinical program for metastatic gastric cancers.

Immunic's phase 3 ENSURE program for vidofludimus calcium in relapsing multiple sclerosis (RMS) continues as planned after a positive interim futility analysis.

I-Mab completed the divestiture of its China operations, streamlining the organization and transitioning to a U.S.-based operating model.

I-Mab is preparing to file an IND for uliledlimab in combination with chemotherapy and checkpoint inhibitors for newly diagnosed NSCLC patients in 1H 2024.

I-Mab reported encouraging Phase Ib/II trial data for uliledlimab combined with toripalimab in treatment-naïve advanced non-small cell lung cancer (NSCLC).